Browsing category:

Antipsychotic


The FDA gave the green light in late May 2015 with their approval of a quarterly dosing schedule of Paliperidone Palmitate, also known as Invega Trinza. Marketed by Janssen Pharmaceuticals this novel dosing regimen is the first ever quarterly dosing therapy for patients with Schizophrenia. Paliperidone is dispensed to patients via an intramuscular injection every[…]

Read More

The USFDA has received the Aripiprazole Lauroxil NDA, submitted by Ireland-based Alkermes for treating patients with schizophrenia. Alkermes shares gained almost 2.3% on the news. Aripiprazole lauroxil is a partial dopamine agonist of the second generation class of antipsychotics, with one-month and two-month formulations, developed for the treatment of the mental disorder schizophrenia, which is[…]

Read More

Alkermes excitedly announced extremely positive study data from a Phase 3 trial of Aripiprazole. This randomized, placebo-controlled and double-blind study gleaned better than expected results, leading pharmaceutical executives at Alkermes to set a plan in motion for an NDA by the third quarter of 2014. As a long acting and injectable antipsychotic treatment Aripiprazole Lauroxil[…]

Read More

As a blockbuster medication used to treat schizophrenia, Aripiprazole CAS# 129722-12-9 has recently been approved by the FDA as a once a month treatment. Marketed by Otsuka and Bristol-Myers Squibb, this monthly dosage of aripiprazole will be sold under the name Abilify Maintena. Aripiprazole is a solid and reliable long-acting antipsychotic medication, and this FDA[…]

Read More

Lurasidone CAS# 367514-87-2, is an atypical antipsychotic medication. Also known as the brand name Latuda, lurasidone is an effectual treatment for the symptoms of schizophrenia. As a second generation antipsychotic, or SGA, lurasidone is available in 20, 40, 80 and 120 milligram tablets. Latuda was approved by the FDA in October of 2010 for the[…]

Read More

Asenapine, also known as Saphris, marketed by Merck, is an efficacious drug for patients suffering from schizophrenia and bipolar disorder. Classified as an antipsychotic medication, Asenapine, CAS# 65576-45-6 is available in sublingual tablets of 5 and 10 milligrams. With the patent of Saphris expiring on June 8, 2015, a generic form of this lifesaving drug[…]

Read More

Ondansetronis also known by the brand name Zofran. As a medication used to prevent nausea and vomiting, geared especially for patients post chemotherapy, radiation or surgery, ondansetron is a 5-HT3 receptor antagonist. By blocking the activity of serotonin, a natural substance believed to cause nausea and vomiting, ondansetron is an effective antiemetic. Offered as a[…]

Read More